Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2018 · 10-K
Revenue$115.93M$115.93M+31.1% vs Q4 2017 Net Income$25.89M$25.89M+89.6% vs Q4 2017 EPS Diluted$0.48$0.48+84.6% vs Q4 2017 Operating Income$39,855,000+16.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$32,753,000−7.9% Margins · derivedOperating margin34.4%−4.5 pt vs Q4 2017
Net margin22.3%+6.9 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 1, 2019 · 60 d after period end